Come meet us at #ENDO2026! Stop by Booth #4407 to connect with our team and learn how the Afirma® GRID (Genomic Resource for Intelligent Discovery), a proprietary research-use-only* database, is designed to help advance the understanding of #ThyroidNodules and #ThyroidCancer at the molecular level. What Can You Do with Afirma GRID Data? We share the Afirma GRID data resource with the research community to help accelerate scientific discoveries. The Afirma GRID data resource enables researchers and clinicians to uncover new insights into thyroid nodule and thyroid cancer biology by providing access to: 🧬 >300K whole-transcriptome profiles 🔒 Up to 46 locked gene expression signatures *Afirma GRID data is for research use only and is not intended to guide patient management. | The Afirma GRID Resources | Learn more about Afirma GRID - afirma.com/afirma-grid/ Download the Afirma 2025 Research Collection - veracyte.com/afirma-2025-res… | Additional ENDO Information | Event information - veracyte.com/company/event/e… Join Us at Exhibit Hall Theater #1: "Afirma Molecular Testing: Unique Situations and New Prognostic Development" 📅 Sunday, June 14  | 2:30–3:30 PM CT #AfirmaThyroid #ThyroidResearch #Endocrinology #GenomicResearch #TeamVeracyte Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit: veracyte.com/legal/cautionar…

We're excited to be back in Chicago this week for the #ENDO2026 Annual Meeting! Just weeks after being here for ASCO, our focus now shifts to learning with and from the #endocrinology community. Be sure to visit Booth #4407 to meet our team and learn how Veracyte utilizes transcriptome-wide analysis on every fine-needle aspiration (FNA) sample to generate an Afirma® Genomic Sequencing Classifier report that provides comprehensive molecular insights to support informed clinical decision-making. Attend our product theater on Sunday, June 14, featuring physicians from Brigham and Women’s Hospital discussing their experience with #AfirmaGSC and how it supports confident thyroid nodule management. | Product Theater Details | Presentation: Afirma Molecular Testing: Unique Situations and New Prognostic Development Presenters: Drs. Athanasios Bikas and Theodora Pappa (Brigham and Women’s Hospital) join Dr. Josh Klopper (Veracyte) 📅 Date / Time: Sunday, June 14 at 2:30 PM – 3:30 PM 📍 Location: Exhibit Hall Theater #1 We look forward to seeing you there! | Resources | 🔗 Event information: veracyte.com/company/event/e… 📄 Download the Afirma 2025 Research Collection: veracyte.com/afirma-2025-res… #Endocrinology #ThyroidNodules #ThyroidHealth #ClinicalEndocrinology Note: veracyte.com/legal/cautionar…

Congratulations to @UCL and the #OPTIMA investigator team on this incredible research featured on BBC Breakfast. 👏 Stories like Aileen Pritchard’s highlight the power of #PrecisionOncology in helping identify patients who can safely avoid unnecessary chemotherapy while still receiving the care that’s right for them. We’re proud that Veracyte was part of this important work. The Prosigna® Breast Risk of Recurrence (ROR) Test is now also available for ordering in the U.S., helping support more personalized treatment decisions for patients with early-stage #BreastCancer. | About Prosigna Test | #ProsignaRORTest Clinical Resources - veracyte.com/tests/prosigna-… How to order the #ProsignaBreastTest - veracyte.com/tests/prosigna-… #Oncology #Prosigna #BreastCancerResearch Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit: veracyte.com/legal/cautionar…

We are thrilled to announce that the Prosigna® Breast Risk of Recurrence (ROR) test, a genomic test for patients diagnosed with early-stage hormone-receptor positive (HR ) breast cancer, is officially available to order in the U.S.! Thank you to @Nasdaq for featuring us on their Times Square tower in honor of this important milestone in breast cancer care. | Impact | In the U.S., more than 225,000 new HR /HER2- breast cancer cases are diagnosed each year. It is critically important to accurately determine a patient's risk of recurrence because the effects of treatment escalation or de-escalation can have a lasting impact on a patient's life. On the heels of the landmark #OPTIMA trial readout at #ASCO26, the #ProsignaTest now offers clinicians and the patients not only a deeper understanding of individual risk of recurrence (ROR) for their hormone receptor positive (HR ) breast cancer, but for many, if chemotherapy can benefit them or if they may safely avoid it. Developed from the #PAM50 genomic classifier, the Prosigna test is the only test that combines intrinsic subtypes and proliferation score with clinical pathological factors to provide a comprehensive 10-year probability of distant recurrence. Additionally, the Prosigna Breast ROR test is the only test proven to be predictive for chemotherapy benefit for premenopausal and post-menopausal patients with high-clinical risk HR breast cancer with up to 9 positive lymph nodes. | Access and Availability | The Prosigna test is available to order through Veracyte's network nationwide via the Veracyte Ordering Portal. The test is currently covered by many commercial payers, and patients may qualify for financial assistance or a tailored payment plan supported by the Veracyte Access Program for eligible uninsured and underinsured patients. 🔗 How to order the Prosigna test - veracyte.com/tests/prosigna-… | Resources | 🔹 Prosigna test clinical resources - veracyte.com/tests/prosigna-… 🔹 View Prosigna test sample reports - veracyte.com/tests/prosigna-… #ProsignaBreastRORTest #BreastCancer #PrecisionMedicine #CancerDiagnostics Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit: veracyte.com/legal/cautionar…

This weekend's #ASCO26 sessions put a spotlight on key advances in urologic cancers. Here's a recap from a session, where Christopher Sweeney, M.B.B.S., Adelaide University, presented new data from the #ENZAMET phase 3 trial. The talk explored whether the Decipher® Prostate Genomic Classifier can identify which patients with metastatic prostate cancer may benefit from adding the chemotherapy docetaxel to androgen deprivation therapy (ADT) plus enzalutamide (also known as triplet therapy), and which may safely avoid it. | Primary Takeaway | 🔹 The #DecipherProstateTest identifies which metastatic prostate cancer patients may benefit from treatment intensification, and which can be safely spared chemotherapy, giving clinicians an actionable, evidence-based answer. 🔹 The ENZAMET findings build on prior validation in the STAMPEDE and CHAARTED trials, where Decipher Prostate identified patients most likely to benefit from adding docetaxel to ADT alone. 🔹 ENZAMET advances that evidence with the first demonstration that the test predicts chemotherapy benefit when added to doublet therapy (ADT plus an androgen receptor pathway inhibitor, like enzalutamide). | Some Thank You's | 💙 We're grateful to Dr. Sweeney for sharing these important findings with the oncology community and for an ongoing commitment to improving care for the millions of men living with prostate cancer worldwide, including about 30,000 in the US who present with metastatic disease at diagnosis.(1,2) 💙 Thank you to everyone who joined the session and to the investigators, site teams, and participants whose contributions made this research possible. | Additional Resources | Learn more about the Decipher Prostate Genomic Classifier - veracyte.com/tests/decipher-… ENZAMET Trial Information - anzup.org.au/clinical-trial/… STAMPEDE Trial Information - investor.veracyte.com/news-r… CHAARTED Trial Information - veracyte.com/resources/scien… | References | (1) cancer.org/cancer/types/pros…; seer.cancer.gov/statfacts/ht… (2) cdc.gov/united-states-cancer… Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit: veracyte.com/legal/cautionar… #DecipherUrologicCancers #ProstateCancer #PrecisionMedicine #ClinicalTrials #TeamVeracyte

We are proud to announce the U.S. commercial launch of the Prosigna® Breast Risk of Recurrence (ROR) test, a genomic test for patients diagnosed with early-stage hormone-receptor positive (HR ) breast cancer. The #ProsignaBreastTest will be available to order starting June 8, 2026. | Impact | On the heels of the landmark #OPTIMA trial readout at #ASCO26, the Prosigna test now offers clinicians and the patients they serve not only a deeper understanding of individual risk of recurrence, but for many, whether chemotherapy can benefit them or whether they may safely avoid it. In the U.S., more than 225,000 new HR /HER2- breast cancer cases are diagnosed each year. When breast cancer is diagnosed early and treated appropriately, five-year survival rates reach 92%(1). It is critically important to accurately determine a patient's risk of recurrence because the effects of treatment escalation or de-escalation have a lasting impact on a patient's life. | Why the Prosigna Test Stands Apart | 🔹 Comprehensive molecular analysis: The Prosigna test was developed from the PAM50 genomic classifier and is the only test that combines intrinsic subtypes and proliferation score with clinical pathological factors to provide a comprehensive 10-year probability of distant recurrence. 🔹 Proven across high-risk populations: Based on the phase III, prospective, OPTIMA trial, the Prosigna test is the only test proven to be predictive for chemotherapy benefit for high-clinical risk patients with up to 9 positive nodes, including premenopausal women treated with ovarian function suppression. 🔹 Superior prognostic accuracy: Extensively validated clinical evidence demonstrates that the Prosigna test is more prognostically accurate than other genomic assays, particularly in the critical 5-10 year breast cancer recurrence window. | Access and Availability | The Prosigna test will be available to order starting June 8, 2026 through Veracyte's network nationwide via the Veracyte Ordering Portal. The test is currently covered by most commercial payers, and patients may qualify for financial assistance or a tailored payment plan supported by the Veracyte Access Program for eligible uninsured and underinsured patients. | Resources | 📄 Read the full press release - investor.veracyte.com/news-r… 🔗 Prosigna clinical resources - veracyte.com/tests/prosigna-… 🔗 Veracyte ordering portal for providers - veracyte.com/portal/#provide… #BreastCancer #PrecisionMedicine #CancerDiagnostics | References | (1) National Breast Cancer Foundation, Inc., Breast Cancer Facts & Stats; Last updated Apr 20, 2026. nationalbreastcancer.org/bre… Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit: veracyte.com/legal/cautionar…

Veracyte is proud to announce new findings from an analysis of patient samples from the ENZAMET trial, an international, randomized Phase III study conducted by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). The analysis demonstrates that the Decipher® Prostate test identifies which men with metastatic prostate cancer may benefit from adding the chemotherapy docetaxel to standard hormonal therapy (also known as triplet therapy), and who may safely avoid it, providing the first Level 1B evidence for a genomic test guiding this decision. | Key Findings | The new ENZAMET trial results provide evidence for genomic-guided decisions on triplet therapy in advanced disease: 🔹Improved outcomes guided by Decipher Prostate: Patients with higher Decipher scores (>0.85) who received triplet therapy had clinically meaningful better survival compared to those on standard hormonal therapy alone. 🔹Patients can be spared from chemotherapy: Patients with lower Decipher scores showed no benefit from adding chemotherapy, suggesting it may be safely avoided. 🔹 Overcoming aggressive disease: Patients with higher Decipher scores who received triplet therapy had more aggressive disease features, yet achieved comparable survival to lower-risk patients on doublet therapy, suggesting chemotherapy offset the poor prognostic effects of aggressive disease biology. Prof. Christopher Sweeney, MBBS, South Australian Immunogenomics Cancer Institute, Adelaide University, will present the ENZAMET trial results at the #ASCO26 Annual Meeting. | Presentation Details | 📅 Date: Saturday, May 30 ⏰ Time: 1:15 PM CDT 📍 Location: Prostate, Testicular, and Penile, Hall D1, Abstract 5001 | Resources | 🤝 Visit Booth 13069: Stop by to connect with #TeamVeracyte and learn how the Decipher Prostate Genomic Classifier test can assess risk of metastasis or metastatic progression in patients with localized or advanced prostate cancer. 🔗 Event information - veracyte.com/company/events-… 📄 Read full press release - investor.veracyte.com/news-r… 🧬 More on the ENZAMET trial - anzup.org.au/clinical-trial/… #DecipherUrologicCancers #ProstateCancer #PrecisionMedicine #ClinicalTrials #CancerDiagnostics Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit - veracyte.com/legal/cautionar…

🚨Happening this afternoon! 🚨 🎤  Hear the Latest Findings from the ENZAMET Phase 3 Trial Christopher Sweeney, MBBS, South Australian Immunogenomics Cancer Institute, Adelaide University, will share the first look at new results from the ENZAMET trial, which assesses whether the Decipher® Prostate Genomic Classifier can predict benefit from adding chemotherapy to androgen deprivation therapy plus enzalutamide) for men with metastatic hormone sensitive prostate cancer. | Session Details | Session: Assessment of the ability of Decipher Prostate Genomic Classifier (DGC) >0.85 to identify patients who benefit from adding docetaxel (DOC) to androgen deprivation therapy (ADT) plus enzalutamide (ENZ): Level 1B evidence from the ENZAMET study 📅 Date / Time: Saturday, May 30, 2026, 3:12 PM CT 📍 Location: Genitourinary Cancer—Prostate, Testicular, and Penile, Hall D1, Abstract 5001 #ProstateCancer #ClinicalTrials #ClinicalResearch #PrecisionMedicine #CancerDiagnostics #OncologyResearch #DecipherUrologicCancers

🚨Today is the day! 🚨 🎤 Don't Miss the First Results from the OPTIMA Trial at #ASCO26 Join Robert Stein, Ph.D., MBBChir, FRC, National Institute for Health Research and University College London Hospitals Biomedical Research Centre, as he presents the first results from the independent #OPTIMA trial evaluating the ability of the Prosigna® Breast Risk of Recurrence (ROR) test to predict which patients with clinically high-risk estrogen receptor (ER) positive and HER2 negative early breast cancer may safely avoid chemotherapy and its side effects without compromising outcomes. | Session Details | Session: First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer 📅 Date / Time: Saturday, May 30, 1:15 PM CDT 📍 Location: Breast Cancer – Local/Regional/Adjuvant, Hall B1, Abstract 500 #BreastCancer #ClinicalTrials #ClinicalResearch #PrecisionMedicine #CancerPrognosis #CancerDiagnostics #OncologyResearch #Prosigna

We are proud to announce results from the landmark independent #OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) trial, led by University College London (@ucl). The results, which will be presented at the #ASCO26 Annual Meeting, conclude that the Prosigna® Breast Risk of Recurrence (ROR) test safely guides adjuvant chemotherapy decisions in patients with early-stage, estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative breast cancer. | Impact | The study shows for the first time, based on the Prosigna test results, that more than 2/3 of patients with clinically high-risk node-positive breast cancer, including premenopausal women and patients with 4 to 9 positive nodes, could safely forgo chemotherapy and its long-term physical and emotional side effects without compromising outcomes. For decades, chemotherapy decisions have relied on clinical factors alone such as age, tumor size, and lymph node status. Today, many node-positive breast cancer patients still receive chemotherapy as standard of care with up to 43% of breast cancer survivors experiencing persistent nerve damage years after chemotherapy.* The Prosigna test determines a patient's ROR score, estimates the 10-year probability of distant recurrence, and identifies patients who can benefit from chemotherapy and those who may safely avoid it. The OPTIMA trial results deliver practice-changing evidence to inform more personalized chemotherapy decision-making. These results show that the Prosigna test can accurately predict chemotherapy benefit and guide safe de-escalation across the broadest set of patients with clinically high-risk breast cancer to-date. Prof. Rob Stein, Lead Investigator, from UCL will present the OPTIMA trial results at the #ASCO2026 Annual Meeting. | Presentation Details | 📅 Saturday, May 30 at 1:15 PM CDT 📍 Location: Breast Cancer – Local/Regional/Adjuvant, Hall B1, Abstract 500 | Resources | 📄  Press release: investor.veracyte.com/news-r… 🔗 Event information - veracyte.com/company/events-… 🧬 More on the OPTIMA trial -optimabreaststudy.com/ | References | (*) Kamgar M, et al. Prevalence and predictors of peripheral neuropathy after breast cancer treatment. Cancer Medicine. 2021;10(19):6666-6676. #ProsignaBreastRORTest #BreastCancer #PrecisionMedicine #ClinicalTrials This article contains forward-looking statements. These forward-looking statements involve risks and uncertainties. Please visit our website for more information:

Veracyte is a proud supporter of @ConquerCancerFd, a non-profit organization that funds cancer research, education, and other vital programs to improve patient outcomes. As part of their mission to accelerate breakthroughs in lifesaving research and empower people everywhere to conquer cancer, they provide funding to support physician-scientists during the early stages of their careers through their Young Investigator Awards (YIA) program. The Conquer Cancer® - Veracyte Endowed Young Investigator Award in Breast Cancer Genomics will be awarded each year. Today, we are excited to congratulate the first recipient: Alexandra Bili Newman, M.D., The University of Texas MD Anderson Cancer Center! Dr. Bili Newman is a second-year Hematology-Oncology fellow at MD Anderson Cancer Center in Houston, TX, with a clinical and research focus in Breast Oncology. Her upcoming YIA project focuses on the role of post-transcriptional PTEN loss as a predictive biomarker of response to PI3K targeted agents in advanced hormone-receptor positive breast cancer. Join us in congratulating Alexandra and the other Conquer Cancer grant and award recipients. #ASCO26 #ConquerCancer #TeamVeracyte #BreastCancer #CancerGenomics

The OPTIMA phase III trial evaluated whether the Prosigna® Breast Risk of Recurrence test can help guide chemotherapy decisions for women with early-stage breast cancer. First results will be presented Saturday, May 30 at #ASCO2026 in Chicago. See the latest coverage in Reuters by @NancyLapid - reuters.com/business/healthc… Join us at #ASCO26 - veracyte.com/company/events-… #ProsignaBreastRORTest #BreastCancer #PrecisionMedicine #ClinicalTrials This article contains forward-looking statements. These forward-looking statements involve risks and uncertainties. Please visit our website for more information -veracyte.com/legal/cautionar…

May is #BladderCancerAwarenessMonth, a moment to recognize the people behind every diagnosis: patients navigating difficult decisions, the friends and family offering support along the way, and the healthcare professionals dedicated to delivering the best possible care. 🔹#BladderCancer is one of the most common cancers worldwide 🔹It does not behave the same way in every person, and differences in tumor biology can influence how the disease progresses and how it is treated 🔹Ongoing advances from the research community continue to deepen our understanding and help guide more personalized treatment decisions At Veracyte, our commitment to advancing bladder cancer science is rooted in evidence, innovation, and collaboration. The #DecipherBladder test is a molecular subtyping tool that reveals underlying biological insights to help bring clarity to bladder cancer treatment decisions. Read our latest blog to learn how molecular insights are helping guide more personalized bladder cancer care: veracyte.com/company/blog/th… #BladderCancer #BladderCancerAwarenessMonth #DecipherBladder #MolecularSubtyping #PrecisionMedicine Note: this information contains forward-looking statements - veracyte.com/legal/cautionar…

Data from two significant phase III clinical trials using our Prosigna Breast and Decipher Prostate tests will be presented at the 2026 American Society of Clinical Oncology Annual Meeting (#ASCO26), taking place May 29 - June 2 in Chicago. The OPTIMA and ENZAMET trial presentations are expected to provide practice-changing evidence demonstrating how Veracyte's genomic tests can guide treatment decisions in both early-stage breast cancer and metastatic prostate cancer. #ProsignaBreast: The results from the #OPTIMA study will address a key clinical question: which breast cancer patients would benefit from chemotherapy, and which may be able to safely avoid it – and its lasting side effects. #DecipherProstate: The independent analysis of results from the #ENZAMET trial will assess the ability of the Decipher Prostate test to identify which patients with metastatic prostate cancer are most likely to benefit from adding chemotherapy to their treatment plan. Read the full press release - investor.veracyte.com/news-r… Event information - veracyte.com/company/event/a… #ASCO2026 #ClinicalTrials #BreastCancer #ProstateCancer #PrecisionMedicine #TeamVeracyte This information contains forward-looking statements - veracyte.com/legal/cautionar…

#TeamVeracyte is in Washington, DC this weekend for the American Urological Association’s (#AUA2026) Annual Meeting, May 15–18. Stop by Booth 3405 to learn how our Decipher tests bring insight to prostate and bladder cancer care. 🔹#DecipherProstate: Delivering genomic information to support clinical decision-making across the prostate cancer continuum 🔹#DecipherBladder: Molecular subtyping that provides deep biological insight to support more individualized bladder cancer care 🔹#DecipherGRID: Proprietary research-use-only database is designed to help advance the understanding of urologic cancers at the molecular level | Resources | 🔗 Event details and full presentation schedule - veracyte.com/company/event/a… #AUA26 #DecipherUrologicCancers #UrologicCancer #ProstateCancer #BladderCancer #PrecisionMedicine #CancerDiagnostics

We received Medicare coverage for our #TrueMRD Monitoring Test for patients with muscle-invasive bladder cancer (MIBC). Available for clinicians to order on June 1, 2026, this marks the commercial launch of Veracyte's first molecular residual disease (#MRD) offering and the only commercially available truly whole-genome MRD test to come to market. 🔗 Read the full press release - investor.veracyte.com/news-r… 🔗 Learn about the TrueMRD Monitoring Test for MIBC -  veracyte.com/tests/truemrd-m… #MuscleInvasiveBladderCancer #BladderCancer #WholeGenomeSequencing $VCYT Disclaimer - veracyte.com/legal/cautionar…

More than 15 studies on our Decipher portfolio will be presented at #AUA2026, May 15–18 in Washington, DC. Data showcases the growing impact of #DecipherBladder and #DecipherProstate tests in supporting personalized patient care. Press release: investor.veracyte.com/news-r… Event info: veracyte.com/company/event/a… #UrologicCancer #ProstateCancer #BladderCancer #PrecisionMedicine Disclaimer: veracyte.com/legal/cautionar…

We will report financial results for the first quarter of 2026 on May 5, 2026 at 4:30 PM ET. Join our conference call and webcast to learn more about the financial results and receive a general business update. Access the live audio webcast here: investor.veracyte.com/events… #Q1Earnings #FinancialResults #InvestorRelations #Biotech #Diagnostics $VCYT #CancerDiagnostics #PrecisionMedicine Note: this information contains forward-looking statements - veracyte.com/cautionary-note…

Exciting news: the #AfirmaGRID data resource is expanding from 36 to 50 data points to further accelerate scientific discoveries in thyroid nodules and thyroid cancer. The Afirma GRID proprietary research-use-only database is designed to help clinicians advance the understanding of thyroid nodules and thyroid cancer at the molecular level. Afirma GRID data has contributed to a growing number of abstracts presented in collaboration with notable institutions from around the world, with a significant increase in research outputs throughout 2025. 🔬 Afirma GRID data is available through three access pathways. Interested in conducting research or learning more? Learn more -  veracyte.com/innovation/afir…  Contact us -  veracyte.com/company/contact… #ThyroidResearch #ThyroidCancer #Endocrinology #GenomicResearch